Abstract | OBJECTIVE: To evaluate the long-term clinical effect of treatment with metreleptin (an analogue of human leptin) on glycemic and lipid abnormalities and markers of hepatic steatosis in patients with inherited or acquired lipodystrophy. METHODS: RESULTS: At baseline, hemoglobin A1c-8.5% ± 2.1% (mean ± standard deviation [SD])-and triglycerides-479 ± 80 mg/dL (geometric mean ± standard error [SE])-were substantially elevated. Robust and sustained reductions in both variables were evident for the observed patient population during a 3-year metreleptin treatment period (-2.1% ± 0.5% [mean ± SE] and -35.4% ± 13.7% [mean ± SE], respectively). Mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at baseline (100 ± 120 U/L and 71 ± 77 U/L [mean ± SD], respectively) and decreased by -45 ± 19 U/L and -33 ± 14 U/L (mean ± SE), respectively, during the 3-year metreleptin treatment period. Improvements in hemoglobin A1c, triglycerides, ALT, and AST were more pronounced in the subsets of patients having elevated levels at baseline. The most notable adverse events observed in this patient population were likely attributable to underlying metabolic abnormalities or comorbidities. CONCLUSION:
|
Authors | Jean L Chan, Karen Lutz, Elaine Cochran, Wenying Huang, Yvette Peters, Christian Weyer, Phillip Gorden |
Journal | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
(Endocr Pract)
2011 Nov-Dec
Vol. 17
Issue 6
Pg. 922-32
ISSN: 1934-2403 [Electronic] United States |
PMID | 22068254
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Biomarkers
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Hypolipidemic Agents
- Leptin
- hemoglobin A1c protein, human
- metreleptin
|
Topics |
- Adolescent
- Adult
- Aged
- Biomarkers
(blood)
- Child
- Cohort Studies
- Fatty Liver
(etiology, prevention & control)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypertriglyceridemia
(etiology, prevention & control)
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Hypolipidemic Agents
(adverse effects, therapeutic use)
- Leptin
(adverse effects, analogs & derivatives, therapeutic use)
- Lipodystrophy
(blood, drug therapy, physiopathology)
- Liver
(physiopathology)
- Male
- Middle Aged
- Time Factors
- Young Adult
|